Organon & Co.: Difference between revisions

Browse history interactively

← Previous edit

Content deleted Content added

VisualWikitext

Revision as of 23:19, 19 January 2023 edit DMc2020 (talk \| contribs) 14 edits m Added link to the official Information Statement filed by Organon. The link is to a U.S. Government website belonging to the Securities & Exchange Commission. ← Previous edit		Latest revision as of 08:14, 21 October 2024 edit undo Latarnie (talk \| contribs) 10 edits m →Products: Made two medical terms into wikilinks.
(28 intermediate revisions by 15 users not shown)
Line 4: \| name = Organon & Co. \| logo = Organon-logo.svg \| type = [[Public company\|Public]] \| traded_as = {{ubl\|{{NYSE\|OGN}}\|[[S&P ~~500~~600]] component}} \| industry = [[Pharmaceuticals]] \| fate = \| predecessor = Organon International (founded 1923)<ref>{{cite web \|title=Organon International 1923 \|url=https://collection.sciencemuseumgroup.org.uk/people/cp28940/organon-international \|publisher=Science Museum Group \|access-date=4 June 2021}}</ref> \| successor = <!-- or: \| successors = --> \| founded = ~~{{Start~~1923 ~~date~~(as ~~and~~Organon ~~age\|~~International)<br>2020}} (as Organon & Co)<ref>{{cite web \|title=OGN - Organon & Co. \|url=https://seekingalpha.com/symbol/OGN/overview \|publisher=Seeking Alpha \|access-date=4 June 2021}}</ref> \| founder = <!-- or: \| founders = --> \| defunct = \| hq_location = ~~{{nowrap\|~~[[~~Jersey~~30 Hudson ~~City, New Jersey~~Street]]~~, U.S.}}~~ \| hq_location_city = {{nowrap\|[[Jersey City, New Jersey]]}} \| hq_location_country = U.S. \| area_served = <!-- or: \| areas_served = --> \| key_people = Kevin Ali, (CEO) \| products = \| revenue = {{Increase}} {{US$\|6.26 billion\|link=yes}} (2023) \| revenue = {{Increase}} {{US$\|6.5 billion\|link=yes}} (2020)<ref>{{Cite web\|url=https://www.businesswire.com/news/home/20210204005437/en/Merck-Announces-Fourth-Quarter-and-Full-Year-2020-Financial-Results\|title = Merck Announces Fourth-Quarter and Full-Year 2020 Financial Results\|date = 4 February 2021}}</ref> \| operating_income = {{Decrease}} {{US$\|1.26 billion}} (2023) \| net_income = {{Increase}} {{US$\|1.02 billion}} (2023) \| assets = {{Increase}} {{US$\|12.1 billion}} (2023) \| equity = {{IncreaseNegative}} {{US$\|-70 million}} (2023) \| owner = <!-- or: \| owners = --> \| num_employees = 9{{circa\|10,000}} (~~2021~~2023) \| website = {{~~url~~URL\|organon.com}} \| footnotes = <ref name=AR2023>{{Cite web \|url=https://www.sec.gov/ix?doc=/Archives/edgar/data/1821825/000162828024006733/ogn-20231231.htm \|title=2023 Annual Report (Form 10-K) \|date=February 26, 2024 \|publisher=U.S. Securities and Exchange Commission}}</ref> }} '''Organon & Co.''' is an American pharmaceutical company headquartered in [[Jersey City, New Jersey]].<ref>[https://www.costar.com/article/1863599073/merck-spinoff-to-locate-headquarters-in-jersey-city-new-jersey costar.com]</ref> Organon specializes in the following core therapeutic fields: [[reproductive medicine]], [[contraception]], [[psychiatry]], [[hormone replacement therapy]] (HRT), and [[anesthesia]]. Organon ~~sells~~produces toall ~~international~~its ~~markets~~products outside of the United States but gets a third of its revenue from the United States.<ref name="202210k"/> ==History== Organon was founded byin ~~Dr.~~1923 as a partnership between the physiologist/endocrinologist of the University of Amsterdam Prof Ernst Laqueur and Saal van Zwanenberg in(1889-1974)<ref>{{cite ~~[[Oss]],~~web ~~[[the~~\|title=Saal ~~Netherlands]],~~van inZwanenberg ~~1923~~\|url=https://www.brabantserfgoed.nl/personen/z/zwanenberg-saal-van as\|website=Brabants aErfgoed ~~separate~~\|access-date=30 ~~part~~May of2023}}</ref> ~~the~~who ~~meat~~owned ~~factory~~an ~~Zwanenberg's~~abattoir/slaughterhouse, ~~fabrieken~~Zwanenbergs Slachterijen en Fabrieken, in [[Oss]] in Northern Brabant. ~~Its~~The company's first product was [[insulin]] in 1923.<ref name="History">{{cite web\|url=http://www.organon.com/about/facts/history/index.asp?year=1920 \|title=Organon History 1920s\|publisher=Organon\|access-date=19 June 2010 \|archive-url = https://web.archive.org/web/20061209230507/http://www.organon.com/about/facts/history/index.asp?year=1920 \|archive-date = 9 December 2006}}</ref> In the thirties it manufactured [[estrogen]]s, in particular estrone under the trade name Menformon.<ref name="History"/> In 1948, Organon acquired the [[Newhouse Research Site\|Newhouse research site]] in [[Scotland]], [[United Kingdom]]. The production of [[cortisone]] was initiated in 1953.<ref name="Years" /> In 1962, it bought the stock of the [[Nederlandsche Cocaïnefabriek]]. The company name was changed to '''Koninklijke Zwanenberg-Organon''' ('''KZO'''), and it merged with the fibre producer AKU in 1969 to become AKZO, later Akzo Nobel. Organon was the human health care business unit of [[Akzo Nobel]]. In 2004, Organon acquired active-pharmaceutical-ingredient producer [[Diosynth]].<ref name="Years">{{cite web\|url=http://www.organon.com/about/facts/history/index.asp?ComponentID=10448&SourcePageID=9171 \|title=81 Years of Organon at a Glance\|publisher=Organon\|access-date=19 June 2010 \|archive-url = https://web.archive.org/web/20050309062056/http://www.organon.com/about/facts/history/index.asp?ComponentID=10448&SourcePageID=9171 \|archive-date = 9 March 2005}}</ref> Organon was initially located in West Orange, New Jersey.<ref>{{Cite web \|title=Organon, West Orange, New Jersey. General entrance view \|url=https://www.loc.gov/item/2018732125/ \|access-date=2024-07-04 \|website=Library of Congress, Washington, D.C. 20540 USA}}</ref><ref>{{Cite news \|last=Bagli \|first=Charles V. \|date=2000-03-20 \|title=Known as Poacher, New Jersey Is Faced By Rival to the West \|url=https://www.nytimes.com/2000/03/20/nyregion/known-as-poacher-new-jersey-is-faced-by-rival-to-the-west.html \|access-date=2024-07-04 \|work=The New York Times \|language=en-US \|issn=0362-4331}}</ref><ref>{{Cite web \|date=2005-03-02 \|title=Coming up on the inside... \|url=https://www.newscientist.com/article/mg18524892-800-coming-up-on-the-inside/ \|access-date=2024-07-04 \|website=New Scientist \|language=en-US}}</ref> In November 2007, [[Schering-Plough]] acquired Organon BioSciences and veterinary pharmaceutical company [[Intervet]] from [[Akzo Nobel]].<ref>{{cite web\|url=http://www.news-medical.net/news/2007/11/20/32697.aspx\|title=Schering-Plough Acquires Organon BioSciences\|date=20 November 2007\|publisher=Medical Net News\|access-date=19 June 2010}}</ref> Schering-Plough transferred Organon to its headquarters in Jersey City, [[New Jersey]].<ref>{{cite web\|title=Why Germany and Much of the European Union is Losing its Pharmaceutical Industry\|url=http://www.aei.org/files/2003/03/18/20030318_Calfee.pdf\|publisher=American Enterprise Institute\|access-date=21 February 2013\|url-status=dead\|archive-url=https://web.archive.org/web/20130709033157/http://www.aei.org/files/2003/03/18/20030318_Calfee.pdf\|archive-date=9 July 2013}}</ref> Two years later, Schering-Plough merged with [[Merck & Co.]], known as Merck Sharp & Dohme or MSD outside the United States and Canada.<ref>{{cite press release\|title=Merck and Schering-Plough to Complete Merger Today \|url=http://www.merck.com/newsroom/news-release-archive/corporate/2009_1103.html \|date=November 3, 2009 \|access-date=2010-07-16 \|publisher=Merck & Co. \|url-status=dead \|archive-url=https://web.archive.org/web/20091107063055/http://www.merck.com/newsroom/news-release-archive/corporate/2009_1103.html \|archive-date=November 7, 2009 }}</ref> In May 2020, Merck & Co. announced that ''Organon & Co.'' will be the name of "the pending spin-off of its women’s health, legacy products, and biosimilars businesses, which the company says is on track to be completed by the end of the first half in 2021."<ref>{{Cite web\|title=Merck & Co. To Move Global HQ; Names Organon as New Spin-off\|url=https://dcatvci.org/pharma-news/6513-merck-co-to-move-global-hq-names-organon-as-new-spin-off\|access-date=2020-08-19\|website=dcatvci.org\|date=14 May 2020}}</ref> Merck completed the spinoff and Organon & Co. became a publicly traded company on 3 June 2021. A copy of the Information Statement sent to Merck shareholders was filed with the U.S. SEC on April 20, 2021, in a Form 10-12B/A, Exhibit 99.1 <ref>{{Cite web\|title=Merck SEC Information Statement\| url=https://www.sec.gov/Archives/edgar/data/1821825/000119312521140380/d56612dex991.htm\|access-date=2023-01-19\|website=sec.gov\|date=20 Apr 2021}}</ref> <ref>{{~~cite~~Cite ~~news~~web \|last=Block \|first=Jonathan \|date=2021-06-03 \|title=Merck spinoff Organon begins trading on the NYSE today; Organon down 5% ~~(updated)~~{{!}} Seeking Alpha \|url=https://seekingalpha.com/news/3702841-merck-spinoff-organon-begins-trading-on-the-nyse-today-merck-down-4 \|access-date=~~4 June 2021~~2023-05-04 \|~~work~~website=~~Seeking Alpha~~seekingalpha.com \|~~date~~language=~~3 June 2021~~en}}</ref> In November 2021, the business announced it would acquire Forendo Pharma and its lead compound, a potentially first-in-class oral [[17β-hydroxysteroid]] [[dehydrogenase]] type 1 inhibitor.<ref>{{Cite web\|url=https://www.biospace.com/article/releases/organon-to-acquire-forendo-pharma/?s=79\|title=Organon to Acquire Forendo Pharma}}</ref><ref>{{Cite web\|url=https://www.biospace.com/article/merck-s-women-s-health-spinoff-organon-acquires-finland-s-forendo/?s=79\|title = Women's Health Gets a Boost as Merck Spinoff Acquires New Pipeline}}</ref> ==Products== Their products are divided into three main categories: [[women's health]] (27% of revenue), [[biosimilars]] (8% of revenue), and established brands (64% of revenue). Women's health products are mainly contraceptives such as ''Nexplanon'', a three-year reversible contraceptive implant, and fertility drugs such as ''Puregon'', a follicle-stimulating hormone drug.<ref name="202210k">{{cite web \|title=Organon & Co. \|url=https://d18rn0p25nwr6d.cloudfront.net/CIK-0001821825/dbe1f0cc-7777-4da0-8dac-df1f56d85fab.pdf \|website=SEC \|publisher=Organon & Co. \|access-date=30 September 2023}}</ref> Biosimilars provide treatment for oncology and immunology at potentially lower cost than other FDA approved treatments.<ref name="202210k"/><ref name="FDAbiosimilars">{{cite web \|title=Biosimilars \|url=https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilars \|website=FDA \|publisher=FDA \|access-date=30 September 2023}}</ref> Organon makes the biosimilar ''Hadlima'' which it compares to [[Humira]]. Their established brands are heavily reliant on sales outside the United States of drugs with generic competition. The cardiovascular products such as ''Vytorin'' make a combined 24% of the company revenue.<ref name="202210k"/> Revenue figures stated with 2022 figures. Products include: [[Esmirtazapine]], [[Remeron]], Remeron SolTab, [[Testosterone propionate/testosterone phenylpropionate/testosterone isocaproate/testosterone decanoate\|Sustanon]], [[Deca-Durabolin]], [[Pregnyl]], [[Implanon]], [[Nuvaring\|NuvaRing]], Marvelon, Desolett and a variety of other contraceptive products. ==Research compounds== Line 62 ⟶ 69: ==External links== * {{commonscat-inline}} {{Official\|https://www.organon.com}}▼ ▲{{Official website\|https://www.organon.com}} {{Finance links \| name = Organon & Co. Line 79 ⟶ 88: {{Authority control}} {{DEFAULTSORT:Organon and Co.}} [[Category:Companies listed on the New York Stock Exchange]] [[Category:Corporate spin-offs]] Line 88 ⟶ 98: [[Category:2007 mergers and acquisitions]] [[Category:Companies based in North Brabant]] [[Category:Organisations based in Oss]] [[Category:Dutch companies established in 1923]]